- Home
- ISPR vs COYA Comparison
ISPR vs COYA Comparison
Compare ISPR & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPR | COYA |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.7M | 97.8M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ISPR | COYA |
|---|---|---|
| Price | $1.62 | $4.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.50 | ★ $15.80 |
| AVG Volume (30 Days) | 70.0K | ★ 164.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,494,304.00 | $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.31 | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $1.19 | $3.71 |
| 52 Week High | $3.87 | $7.75 |
Technical Indicators
Market Signals| Indicator | ISPR | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 61.23 |
| Support Level | $1.57 | $4.50 |
| Resistance Level | $1.98 | $5.14 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 52.38 | 70.65 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.